title: Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines.
abstract: To evaluate the antiproliferative activity of a novel BET Bromodomain inhibitor as single agent and in combination with the BTK inhibitor ibrutinib in non-Hodgkin lymphoma cell lines, we performed the MTT proliferation assay. This assay is based on the direct correlation between absorbance (measured colorimetrically at a wavelength of 570 nm) and cell proliferation. Thiazolyl Blue Tetrazolium Blue (MTT) is a yellowish solution that distinguishes between proliferating and dead cells since it is converted to water-insoluble MTT-formazan of dark blue color by mitochondrial dehydrogenases of living cells only.
authors.affiliation: Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Via Vincenzo Vela 6, 6500, Bellinzona, Switzerland.
authors.forename: Elena
authors.initials: E
authors.lastname: Bernasconi
authors.affiliation: Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Via Vincenzo Vela 6, 6500, Bellinzona, Switzerland.
authors.forename: Eugenio
authors.initials: E
authors.lastname: Gaudio
authors.affiliation: Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Via Vincenzo Vela 6, 6500, Bellinzona, Switzerland.|Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland.|Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
authors.forename: Ivo
authors.initials: I
authors.lastname: Kwee
authors.affiliation: Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Via Vincenzo Vela 6, 6500, Bellinzona, Switzerland. frbertoni@mac.com.|IOSI Oncology Institute of Southern Switzerland, Via Vincenzo Vela 6, 6500, Bellinzona, Switzerland. frbertoni@mac.com.
authors.forename: Francesco
authors.initials: F
authors.lastname: Bertoni
mesh_terms: D000083:Acetanilides / Q000494:pharmacology*; D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D006575:Heterocyclic Compounds, 3-Ring / Q000494:pharmacology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism*; D010880:Piperidines; D011720:Pyrazoles / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D000083:Acetanilides; D000970:Antineoplastic Agents; D006575:Heterocyclic Compounds, 3-Ring; C000605331:OTX015; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: BET inhibitor; BRD inhibitor; Ibrutinib; Lymphoma; MTT